Equities researchers at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
AKTX has been the topic of a number of other research reports. HC Wainwright initiated coverage on Akari Therapeutics in a report on Monday, December 5th. They set a “buy” rating and a $1.50 target price on the stock. Alliance Global Partners began coverage on Akari Therapeutics in a research report on Tuesday, November 1st. They set a “buy” rating and a $4.00 price target on the stock.
Akari Therapeutics Trading Up 2.9 %
Shares of AKTX opened at $0.53 on Friday. Akari Therapeutics has a 1 year low of $0.38 and a 1 year high of $1.61. The stock has a market cap of $39.10 million, a P/E ratio of -1.50 and a beta of 1.32. The stock’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $0.78.
Institutional Investors Weigh In On Akari Therapeutics
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.
- Get a free copy of the StockNews.com research report on Akari Therapeutics (AKTX)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don’t Buy It Just Yet
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.